TNYA
Tenaya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.37
+2.66%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.38
From 52W high−75.98%
Volume1.59M
Market cap$84.31M
P/E (TTM)—
P/S (TTM)63.2x
Div yield—
Key dataNov 4, 2026
Open
$0.38
From 52W high
−75.98%
Volume
1.59M
Market cap
$84.31M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
32.2
MomentumView details →
1D Return
+2.66%
YTD Return
−47.03%
SummaryUpdated Jun 1, 2026
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is a biotechnology company founded in 2016 and headquartered in South San Francisco, California. The company went public in July 2021 and focuses on developing innovative therapies for heart disease through three distinct technological platforms: cellular regeneration, gene therapy, and precision medicine. Since its inception, Tenaya has been dedicated to addressing the significant unmet medical needs in cardiovascular medicine, particularly targeting genetic forms of heart disease that currently have limited treatment options.
Similar companies
Latest newsMore news →
The U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to Tenaya Therapeutics' TN-401 for the treatment of PKP2-associated arrhythmogenic right ventricular cardiomyopathy.51d agoTenaya Therapeutics granted stock options to its newly appointed CFO Eric Hyllengren and two new non-executive employees upon their employment commencement.113d ago